These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21935334)

  • 21. Predictors of duloxetine adherence and persistence in patients with fibromyalgia.
    Cui Z; Zhao Y; Novick D; Faries D
    J Pain Res; 2012; 5():193-201. PubMed ID: 22792005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
    Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
    Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vortioxetine for depression in adults.
    Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L
    J Affect Disord; 2016 May; 196():225-33. PubMed ID: 26938965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
    Esposito D; Wahl P; Daniel G; Stoto MA; Erder MH; Croghan TW
    Clin Ther; 2009 Mar; 31(3):644-56. PubMed ID: 19393855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
    Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
    CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use and treatment modalities for SSRI and SNRI antidepressants in Italy during the period 2003-2009.
    Aguglia E; Ravasio R; Simonetti M; Pecchioli S; Mazzoleni F
    Curr Med Res Opin; 2012 Sep; 28(9):1475-84. PubMed ID: 22809113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
    Bielski RJ; Ventura D; Chang CC
    J Clin Psychiatry; 2004 Sep; 65(9):1190-6. PubMed ID: 15367045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
    Sullivan PW; Valuck R; Saseen J; MacFall HM
    CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative assessment of adherence measures and resource use in SSRI/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy.
    Wade RL; Kindermann SL; Hou Q; Thase ME
    J Manag Care Pharm; 2014 Jan; 20(1):76-85. PubMed ID: 24372461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.
    Vlahiotis A; Devine ST; Eichholz J; Kautzner A
    J Manag Care Pharm; 2011 Mar; 17(2):123-32. PubMed ID: 21348545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK.
    Wade AG; Saragoussi D; Despiégel N; François C; Guelfucci F; Toumi M
    Curr Med Res Opin; 2010 May; 26(5):1161-70. PubMed ID: 20297951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
    Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
    J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Escitalopram in the treatment of major depressive disorder: a meta-analysis.
    Kennedy SH; Andersen HF; Thase ME
    Curr Med Res Opin; 2009 Jan; 25(1):161-75. PubMed ID: 19210149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland.
    Benedict A; Arellano J; De Cock E; Baird J
    J Affect Disord; 2010 Jan; 120(1-3):94-104. PubMed ID: 19497623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
    Lam RW; Lönn SL; Despiégel N
    Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials.
    Vis PM; van Baardewijk M; Einarson TR
    Ann Pharmacother; 2005 Nov; 39(11):1798-807. PubMed ID: 16189284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.